Shaperon Inc.
Financials
Valuation Metrics
Shaperon Inc.'s Market Cap is ₩217B. At end of 2025 it was ₩805B. Ranked #2252 of 2,412 in KR market (top 93%), #1490 of 1,632 on KOSDAQ (top 91%), #224 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 21.73B KRW | KR#2,252/2,412 Sec#224/231 |
| Revenue | 322.6M KRW | KR#2,383/2,412 Sec#222/231 |
| Net Income | -15.83B KRW | KR—/2,412 Sec—/231 |
| Total Assets | 29.18B KRW | KR#2,336/2,412 Sec#222/231 |
| Net Assets | 19.03B KRW | KR#2,298/2,412 Sec#215/231 |
| Employees | 54 | KR#2,016/2,412 Sec#185/231 |
| Value | ||
| P/B | 1.13x | KR#1,623/2,412 Sec#102/231 |
| P/S | 66.37x | KR#2,372/2,412 Sec#201/231 |
| FCF Yield | -66.85% | KR—/2,412 Sec—/231 |
| Profitability | ||
| ROE | -83.21% | KR#2,323/2,412 Sec#213/231 |
| ROA | -54.26% | KR#2,364/2,412 Sec#218/231 |
| Op. Margin | -4840.89% | KR#2,380/2,412 Sec#222/231 |
| Revenue Growth | 1186.70% | KR#5/2,412 Sec#3/231 |
| Financial Health | ||
| Debt Ratio | 53.35% | KR#1,004/2,412 Sec#117/231 |
| Total Debt | 7.65B KRW | KR#1,696/2,412 Sec#156/231 |
| FCF | -14.53B KRW | KR#1,807/2,412 Sec#168/231 |
| Cash | 991.4M KRW | KR#2,330/2,412 Sec#221/231 |
| Current Ratio | 3.01x | KR#552/2,412 Sec#76/231 |
| Performance | ||
| 1Y Return | -76.66% | KR#2,351/2,412 Sec#225/231 |
| 1M Return | -12.14% | KR#1,415/2,412 Sec#162/231 |
| From 52W High | -85.11% | KR#2,375/2,412 Sec#224/231 |
| 1Y MDD | -85.62% | KR#2,367/2,412 Sec#222/231 |
| Trading | ||
| Volume | 37,765 shares | KR#1,068/2,412 Sec#109/231 |
| Trading Value | 86.5M KRW | KR#1,482/2,412 Sec#165/231 |
| Foreign Own. | 5.82% | KR#751/2,412 Sec#69/231 |
| Per Share | ||
| EPS | -1,712 KRW | KR—/2,412 Sec—/231 |
| BPS | 2,057 KRW | KR#2,067/2,412 Sec#172/231 |
Company Info
SHAPERON, established in 2008 and listed on KOSDAQ in 2022, is a bio-venture company specializing in new drug candidate development. It expanded its global presence by establishing a U.S. subsidiary in 2023. The company possesses the world's first GPCR19 target-based inflammation inhibitor platform and a nanobody antibody development platform, with various therapeutics in clinical development. SHAPERON is accelerating new drug candidate discovery through an AI-based platform, established after its innovative new drug research center in 2023, and is headquartered in Gangnam-gu, Seoul.